Justin C Voog1, Rebecca Paulus2, William U Shipley3, Matthew R Smith3, David G McGowan4, Christopher U Jones5, Jean-Paul Bahary6, Kenneth L Zeitzer7, Luis Souhami8, Mark H Leibenhaut5, Marvin Rotman9, Siraj M Husain10, Elizabeth Gore11, Adam Raben12, Susan Chafe4, Howard M Sandler13, Jason A Efstathiou14. 1. Harvard Radiation Oncology Program, Boston, MA, USA. 2. NRG Oncology Statistics and Data Management Center, Philadelphia, PA, USA. 3. Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA. 4. Cross Cancer Institute, Edmonton, Alberta, Canada. 5. Sutter Cancer Centers (Radiological Associates of Sacramento), Sacramento, CA, USA. 6. CHUM-Hospital Norte-Dame, Montreal, Quebec, Canada. 7. Department of Radiation Oncology, Albert Einstein Medical Center, Philadelphia, PA, USA. 8. McGill University, Montreal, Quebec, Canada. 9. Brooklyn MB-CCOP/SUNY Downstate, Brooklyn, NY, USA. 10. Tom Baker Cancer Center, Calgary, Alberta, Canada. 11. Medical College of Wisconsin, Milwaukee, WI, USA. 12. Christiana Care Health Services, Inc. CCOP, Newark, DE, USA. 13. Cedars-Sinai Medical Center, Los Angeles, CA, USA. 14. Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA. Electronic address: jefstathiou@partners.org.
Abstract
BACKGROUND:Androgen deprivation therapy (ADT) is associated with coronary heart disease and diabetes in men with prostate cancer (PCa); however, controversy exists regarding ADT and cardiovascular mortality (CVM) with limited data for lower risk disease. OBJECTIVE: We conducted a hypothesis-generating retrospective analysis to evaluate the relationship between short-course ADT and CVM in patients with clinically localized PCa enrolled in a phase III trial. DESIGN, SETTING, AND PARTICIPANTS: A total of 1979 men with clinically localized (T1b-2b, prostate-specific antigen [PSA] <20 ng/ml) PCa enrolled in Radiation Therapy Oncology Group (RTOG) 94-08 from 1994 to 2001. Patients were randomized to radiation therapy (RT) with or without short-course ADT (4 mo of gonadotropin-releasing hormone (GnRH) agonist therapy and antiandrogen). Median follow-up was 9.1 yr for survivors. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: The Cox proportional hazards model assessed overall survival. The Fine-Gray proportional hazards model assessed disease-specific survival (DSS) and CVM. Covariates included age, race, weight, baseline cardiovascular disease, baseline diabetes, baseline hypertension, Gleason score, T stage, and PSA. RESULTS AND LIMITATIONS: Short-course ADT improved overall survival and DSS and was not associated with an increased risk of CVM. Overall, 191 cardiovascular-related deaths were observed. At 10 yr, 83 patients (cumulative incidence rate: 10%) receiving RT and ADT versus 95 patients (cumulative incidence rate: 11%) receiving RT alone experienced CVM. The treatment arm was not associated with increased CVM (unadjusted hazard ratio: 1.07; confidence interval, 0.81-1.42; p=0.62). Increased CVM was not observed in patients at low risk of PCa death or at high risk of cardiac-related death. CONCLUSIONS: Data from patients enrolled in RTOG 94-08 support the hypothesis that ADT does not increase CVM risk in men with clinically localized PCa treated with short-course GnRH agonist therapy. These data support ADT use in settings with proven survival benefit. PATIENT SUMMARY: We investigated the controversial relationship between hormone therapy and cardiovascular mortality in men with prostate cancer (PCa) treated with radiation in a large randomized trial. Our data suggest that hormone therapy does not increase the risk of cardiovascular death in patients with clinically localized PCa and support the use of such therapy in settings with proven survival benefit.
RCT Entities:
BACKGROUND: Androgen deprivation therapy (ADT) is associated with coronary heart disease and diabetes in men with prostate cancer (PCa); however, controversy exists regarding ADT and cardiovascular mortality (CVM) with limited data for lower risk disease. OBJECTIVE: We conducted a hypothesis-generating retrospective analysis to evaluate the relationship between short-course ADT and CVM in patients with clinically localized PCa enrolled in a phase III trial. DESIGN, SETTING, AND PARTICIPANTS: A total of 1979 men with clinically localized (T1b-2b, prostate-specific antigen [PSA] <20 ng/ml) PCa enrolled in Radiation Therapy Oncology Group (RTOG) 94-08 from 1994 to 2001. Patients were randomized to radiation therapy (RT) with or without short-course ADT (4 mo of gonadotropin-releasing hormone (GnRH) agonist therapy and antiandrogen). Median follow-up was 9.1 yr for survivors. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: The Cox proportional hazards model assessed overall survival. The Fine-Gray proportional hazards model assessed disease-specific survival (DSS) and CVM. Covariates included age, race, weight, baseline cardiovascular disease, baseline diabetes, baseline hypertension, Gleason score, T stage, and PSA. RESULTS AND LIMITATIONS: Short-course ADT improved overall survival and DSS and was not associated with an increased risk of CVM. Overall, 191 cardiovascular-related deaths were observed. At 10 yr, 83 patients (cumulative incidence rate: 10%) receiving RT and ADT versus 95 patients (cumulative incidence rate: 11%) receiving RT alone experienced CVM. The treatment arm was not associated with increased CVM (unadjusted hazard ratio: 1.07; confidence interval, 0.81-1.42; p=0.62). Increased CVM was not observed in patients at low risk of PCa death or at high risk of cardiac-related death. CONCLUSIONS: Data from patients enrolled in RTOG 94-08 support the hypothesis that ADT does not increase CVM risk in men with clinically localized PCa treated with short-course GnRH agonist therapy. These data support ADT use in settings with proven survival benefit. PATIENT SUMMARY: We investigated the controversial relationship between hormone therapy and cardiovascular mortality in men with prostate cancer (PCa) treated with radiation in a large randomized trial. Our data suggest that hormone therapy does not increase the risk of cardiovascular death in patients with clinically localized PCa and support the use of such therapy in settings with proven survival benefit.
Authors: Paul L Nguyen; Youjin Je; Fabio A B Schutz; Karen E Hoffman; Jim C Hu; Arti Parekh; Joshua A Beckman; Toni K Choueiri Journal: JAMA Date: 2011-12-07 Impact factor: 56.272
Authors: Urs E Studer; Peter Whelan; Walter Albrecht; Jacques Casselman; Theo de Reijke; Dieter Hauri; Wolfgang Loidl; Santiago Isorna; Subramanian K Sundaram; Muriel Debois; Laurence Collette Journal: J Clin Oncol Date: 2006-04-20 Impact factor: 44.544
Authors: James W Denham; Allison Steigler; David S Lamb; David Joseph; Hedy Mameghan; Sandra Turner; John Matthews; Ian Franklin; Chris Atkinson; John North; Michael Poulsen; David Christie; Nigel A Spry; Keen-Hun Tai; Chris Wynne; Gillian Duchesne; Olga Kovacev; Catherine D'Este Journal: Lancet Oncol Date: 2005-11 Impact factor: 41.316
Authors: M V Pilepich; R Caplan; R W Byhardt; C A Lawton; M J Gallagher; J B Mesic; G E Hanks; C T Coughlin; A Porter; W U Shipley; D Grignon Journal: J Clin Oncol Date: 1997-03 Impact factor: 44.544
Authors: Matthew R Smith; Joel S Finkelstein; Francis J McGovern; Anthony L Zietman; Mary Anne Fallon; David A Schoenfeld; Philip W Kantoff Journal: J Clin Endocrinol Metab Date: 2002-02 Impact factor: 5.958
Authors: Michel Bolla; Laurence Collette; Léo Blank; Padraig Warde; Jean Bernard Dubois; René-Olivier Mirimanoff; Guy Storme; Jacques Bernier; Abraham Kuten; Cora Sternberg; Johan Mattelaer; José Lopez Torecilla; J Rafael Pfeffer; Carmel Lino Cutajar; Alfredo Zurlo; Marianne Pierart Journal: Lancet Date: 2002-07-13 Impact factor: 79.321
Authors: Gerald E Hanks; Thomas F Pajak; Arthur Porter; David Grignon; Harmart Brereton; Varagur Venkatesan; Eric M Horwitz; Colleen Lawton; Seth A Rosenthal; Howard M Sandler; William U Shipley Journal: J Clin Oncol Date: 2003-11-01 Impact factor: 44.544
Authors: William U Shipley; Wendy Seiferheld; Himanshu R Lukka; Pierre P Major; Niall M Heney; David J Grignon; Oliver Sartor; Maltibehn P Patel; Jean-Paul Bahary; Anthony L Zietman; Thomas M Pisansky; Kenneth L Zeitzer; Colleen A F Lawton; Felix Y Feng; Richard D Lovett; Alexander G Balogh; Luis Souhami; Seth A Rosenthal; Kevin J Kerlin; James J Dignam; Stephanie L Pugh; Howard M Sandler Journal: N Engl J Med Date: 2017-02-02 Impact factor: 91.245
Authors: Christopher U Jones; Stephanie L Pugh; Howard M Sandler; Michael P Chetner; Mahul B Amin; Deborah W Bruner; Anthony L Zietman; Robert B Den; Mark H Leibenhaut; John M Longo; Jean-Paul Bahary; Seth A Rosenthal; Luis Souhami; Jeff M Michalski; Alan C Hartford; Pradip P Amin; Mack Roach; Don Yee; Jason A Efstathiou; Joseph P Rodgers; Felix Y Feng; William U Shipley Journal: Int J Radiat Oncol Biol Phys Date: 2021-09-01 Impact factor: 7.038
Authors: Andrea Kokorovic; Alan I So; Hosam Serag; Christopher French; Robert J Hamilton; Jason P Izard; Jasmir G Nayak; Frédéric Pouliot; Fred Saad; Bobby Shayegan; Armen Aprikian; Ricardo A Rendon Journal: Can Urol Assoc J Date: 2022-08 Impact factor: 2.052
Authors: Ruth E Ashton; Garry A Tew; Wendy A Robson; John M Saxton; Jonathan J Aning Journal: Support Care Cancer Date: 2019-04-10 Impact factor: 3.603